Merck commences Phase III trial of DLBCL treatment

Merck has commenced the Phase III waveLINE-010 trial to assess its investigational antibody-drug conjugate (ADC), zilovertamab vedotin, combined with rituximab plus cyclophosphamide, doxorubicin, and prednisone (R-CHP), to treat individuals with previously untreated diffuse large B-cell lymphoma (DLBCL).